AA
ADMA icon

ALPS Advisors’s ADMA Biologics ADMA Stock Holding History

ALPS Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Buy
33,164
+474
+1% +$4.32K ﹤0.01% 1091
2026
Q1 		$295K Buy
+32,690
New +$516K ﹤0.01% 977
2025
Q3 		– Sell
-19,484
Closed -$355K – 1023
2025
Q2 		$355K Buy
19,484
+236
+1% +$4.81K ﹤0.01% 858
2025
Q1 		$382K Sell
19,248
-2
-0% -$35 ﹤0.01% 637
2024
Q4 		$330K Sell
19,250
-400
-2% -$7.53K ﹤0.01% 835
2024
Q3 		$393K Buy
+19,650
New +$306K ﹤0.01% 660

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

ALPS Advisors's ADMA Position: Q2 2026 in Review

ALPS Advisors increased its ADMA Biologics (ADMA) stake by 1.4% in Q2 2026, buying an estimated $4.32K and bringing the position to 33,164 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

ALPS Advisors first reported a position in ADMA in Q3 2024 and has held it in 6 quarters since. The position peaked at $393K in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • ALPS Advisors held 33,164 shares of ADMA Biologics worth $278K as of Q2 2026.
  • ALPS Advisors bought 474 ADMA Biologics shares in Q2 2026, an estimated $4.32K.
  • ADMA Biologics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1091 holding.
  • ALPS Advisors first reported a position in ADMA Biologics in Q3 2024 and has held it in 6 quarters since.
  • ALPS Advisors's ADMA Biologics position peaked at $393K in Q3 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.